146 related articles for article (PubMed ID: 8707164)
21. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
22. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
Cvirn G; Wagner T; Juergens G; Koestenberger M
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
Bendetowicz AV; Béguin S; Caplain H; Hemker HC
Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit.
Carrie D; Caranobe C; Boneu B
Br J Haematol; 1993 Apr; 83(4):622-6. PubMed ID: 8390849
[TBL] [Abstract][Full Text] [Related]
25. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
[TBL] [Abstract][Full Text] [Related]
26. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
27. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
Schoen P; Lindhout T; Hemker HC
Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
[TBL] [Abstract][Full Text] [Related]
28. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
29. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
Fareed J; Hoppensteadt D; Walenga J; Iqbal O; Ma Q; Jeske W; Sheikh T
Clin Pharmacokinet; 2003; 42(12):1043-57. PubMed ID: 12959635
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of low molecular weight heparins.
Bara L; Samama M
Acta Chir Scand Suppl; 1988; 543():65-72. PubMed ID: 2847460
[TBL] [Abstract][Full Text] [Related]
32. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
[TBL] [Abstract][Full Text] [Related]
33. Comparative inhibition of LPS-activated human monocyte-induced thrombin generation by unfractionated heparin and low molecular weight heparins.
Nguyên P; Rémy MG; Potron G
Haemostasis; 1999; 29(6):301-9. PubMed ID: 10844403
[TBL] [Abstract][Full Text] [Related]
34. Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
Kalaska B; Kaminski K; Miklosz J; Yusa SI; Sokolowska E; Blazejczyk A; Wietrzyk J; Kasacka I; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
Transl Res; 2016 Nov; 177():98-112.e10. PubMed ID: 27456749
[TBL] [Abstract][Full Text] [Related]
35. Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin.
Brieger D; Dawes J
Thromb Haemost; 1996 May; 75(5):740-6. PubMed ID: 8725716
[TBL] [Abstract][Full Text] [Related]
36. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
37. In vivo age dependency of unfractionated heparin in infants and children.
Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
[TBL] [Abstract][Full Text] [Related]
38. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma.
Hemker HC; Béguin S
Haemostasis; 1990; 20 Suppl 1():81-92. PubMed ID: 1964667
[TBL] [Abstract][Full Text] [Related]
39. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026.
Viskov C; Just M; Laux V; Mourier P; Lorenz M
J Thromb Haemost; 2009 Jul; 7(7):1143-51. PubMed ID: 19422447
[TBL] [Abstract][Full Text] [Related]
40. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.
Agnelli G; Iorio A; Renga C; Boschetti E; Nenci GG; Ofosu FA; Hirsh J
Circulation; 1995 Nov; 92(10):2819-24. PubMed ID: 7586247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
